KR20120061053A - 유도 만능 줄기(iPS) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템 - Google Patents

유도 만능 줄기(iPS) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템 Download PDF

Info

Publication number
KR20120061053A
KR20120061053A KR1020127006735A KR20127006735A KR20120061053A KR 20120061053 A KR20120061053 A KR 20120061053A KR 1020127006735 A KR1020127006735 A KR 1020127006735A KR 20127006735 A KR20127006735 A KR 20127006735A KR 20120061053 A KR20120061053 A KR 20120061053A
Authority
KR
South Korea
Prior art keywords
ile
asn
ser
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127006735A
Other languages
English (en)
Korean (ko)
Inventor
융 니엔 창
조지 에이. 오일러
Original Assignee
시냅틱 리서치, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시냅틱 리서치, 엘엘씨 filed Critical 시냅틱 리서치, 엘엘씨
Publication of KR20120061053A publication Critical patent/KR20120061053A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0607Non-embryonic pluripotent stem cells, e.g. MASC
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • C12N2501/602Sox-2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • C12N2501/603Oct-3/4
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020127006735A 2009-08-27 2010-08-27 유도 만능 줄기(iPS) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템 Withdrawn KR20120061053A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27529709P 2009-08-27 2009-08-27
US61/275,297 2009-08-27
PCT/US2010/047056 WO2011031568A2 (en) 2009-08-27 2010-08-27 A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS

Publications (1)

Publication Number Publication Date
KR20120061053A true KR20120061053A (ko) 2012-06-12

Family

ID=43625491

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127006735A Withdrawn KR20120061053A (ko) 2009-08-27 2010-08-27 유도 만능 줄기(iPS) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템

Country Status (7)

Country Link
US (2) US8420352B2 (enExample)
EP (1) EP2470664A4 (enExample)
JP (1) JP2013503198A (enExample)
KR (1) KR20120061053A (enExample)
CN (1) CN102612562A (enExample)
CA (1) CA2772400A1 (enExample)
WO (1) WO2011031568A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031568A2 (en) * 2009-08-27 2011-03-17 Synaptic Research, Llc A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
US9410128B2 (en) * 2011-02-22 2016-08-09 Sanford-Burnham Medical Research Institute Method and compounds for generation of iPSCs
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌(Clostridium difficile)之突變毒素有關之組成物及彼之方法
ES2653249T3 (es) * 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
AU2014301116B2 (en) 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
KR20170020431A (ko) 2014-06-27 2017-02-22 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 변이형 헤마글루티닌 복합체 단백질, 및 그것을 사용한 다능성을 갖는 간세포의 배양 방법
US10633643B2 (en) 2015-05-15 2020-04-28 Board Of Regents Of The University Of Nebraska Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
WO2020055915A1 (en) 2018-09-10 2020-03-19 Kavazanjian Edward Biocementation systems and methods
CA3174599A1 (en) * 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN113563428B (zh) * 2021-06-22 2022-08-02 呈诺再生医学科技(珠海横琴新区)有限公司 特定空间结构多肽及其在制备iPSC中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086900A (en) 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
EP1173192B1 (en) 1999-03-08 2018-08-15 Gerhart Graupner Methods and compositions for targeted drug delivery
WO2001011960A1 (en) 1999-08-18 2001-02-22 Agrivax, Inc. A mucosal specific gene delivery system based on modified bacterial exotoxin
US7906103B2 (en) 2000-03-08 2011-03-15 Gerhard Graupner Methods and compositions for targeted drug delivery
US20030166160A1 (en) 2001-09-06 2003-09-04 Hawley Stephen B. Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
IL155204A0 (en) 2000-10-02 2003-11-23 Arizeke Pharmaceuticals Inc Compositions and methods for the transport of biologically active agents across cellular barriers
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
EP1531859A4 (en) 2002-05-31 2005-12-07 Univ Jefferson COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT
GB0216865D0 (en) 2002-07-19 2002-08-28 Microbiological Res Authority Targetted agents for nerve regeneration
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US20090203141A1 (en) 2003-05-15 2009-08-13 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agents
US20050147593A1 (en) 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US20050153923A1 (en) 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
TW200640493A (en) 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
EP2164951A2 (en) * 2007-05-30 2010-03-24 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009073523A2 (en) 2007-11-29 2009-06-11 Children's Hospital Of Orange County De-differentiation of human cells
EP2224940A1 (en) 2007-11-30 2010-09-08 Cytomatrix PTY LTD Methods of inducing pluripotency involving oct4 protein
US20110190729A1 (en) 2007-11-30 2011-08-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
WO2009102983A2 (en) 2008-02-15 2009-08-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
CA2695590C (en) 2008-06-27 2018-01-09 Kyoto University Method of efficiently establishing induced pluripotent stem cells
EP2307539B1 (en) 2008-07-30 2014-11-19 Kyoto University Method of efficiently establishing induced pluripotent stem cells
CN102272290B (zh) 2008-10-09 2018-08-14 米纳瓦生物技术公司 用于在细胞中诱导多能性的方法
JP2012507258A (ja) 2008-10-30 2012-03-29 国立大学法人京都大学 人工多能性幹細胞の作製方法
WO2011031568A2 (en) * 2009-08-27 2011-03-17 Synaptic Research, Llc A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS

Also Published As

Publication number Publication date
US9102921B2 (en) 2015-08-11
CA2772400A1 (en) 2011-03-17
CN102612562A (zh) 2012-07-25
US20110053244A1 (en) 2011-03-03
WO2011031568A3 (en) 2011-10-13
JP2013503198A (ja) 2013-01-31
EP2470664A4 (en) 2013-01-16
US8420352B2 (en) 2013-04-16
EP2470664A2 (en) 2012-07-04
US20130288374A1 (en) 2013-10-31
WO2011031568A2 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
KR20120061053A (ko) 유도 만능 줄기(iPS) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템
Do Kwon et al. Cellular manipulation of human embryonic stem cells by TAT-PDX1 protein transduction
US9005967B2 (en) Myc variants improve induced pluripotent stem cell generation efficiency
Zhang et al. Reprogramming of somatic cells via TAT-mediated protein transduction of recombinant factors
US20110177557A1 (en) Fusion Protein and Use Thereof
Bosnali et al. Generation of transducible versions of transcription factors Oct4 and Sox2.
Yang et al. HIV‐1 TAT‐mediated protein transduction and subcellular localization using novel expression vectors1
US20140127806A1 (en) Modified laminin and use thereof
KR101964863B1 (ko) 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
US10508265B2 (en) Cell-permeable reprogramming factor (iCP-RF) recombinant protein and use thereof
Dey et al. Thummer. Cell-Penetrating Peptides as a Tool to Deliver Biologically Active Recombinant Proteins to Generate Transgene-Free Induced Pluripotent Stem Cells
US9644185B2 (en) Cell permeable fusion protein for facilitating reprogramming induction and use thereof
CA2903933C (en) Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells
Noda et al. Transduction of MyoD protein into myoblasts induces myogenic differentiation without addition of protein transduction domain
Berthoin et al. Targeted release of transcription factors for cell reprogramming by a natural micro-syringe
Lan et al. Expression of biologically active TAT-fused recombinant islet transcription factors
JP2010110289A (ja) iPS細胞の樹立法
Heffernan et al. Temporal requirements of cMyc protein for reprogramming mouse fibroblasts
JP5637354B2 (ja) 精製転写因子の調製法と細胞導入技術
Hidema et al. Effects of protein transduction with intact myogenic transcription factors tagged with HIV-1 Tat-PTD (T-PTD) on myogenic differentiation of mouse primary cells
Konno et al. Intracellular reactivation of transcription factors fused with protein transduction domain
Heffernan et al. Research Article Temporal Requirements of cMyc Protein for Reprogramming Mouse Fibroblasts
Nakagawa i, United States Patent (10) Patent No.: US 9.005967 B2
Libetti Role of NF-YA isoforms in mouse Embryonic Stem Cells and Myoblasts differentiation
Lin et al. The J‐Domain of Heat Shock Protein 40 Can Enhance the Transduction Efficiency of Arginine‐Rich Cell‐Penetrating Peptides

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120315

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid